Stoke Therapeutics (STOK) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Stoke Therapeutics (STOK) overview

Stoke Therapeutics (STOK) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 184m and operating profit of USD -20.6m; the year-end share price was 31.74 USD and market capitalisation was USD 1,870m. Stoke Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Stoke Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 352mFY 2025
Share price31.74 USDFY 2025 year end
RevenueUSD 184mFY 2025
Operating profitUSD -20.6mFY 2025
Net earningsUSD -6.9mFY 2025
Market capitalisationUSD 1,870mFY 2025 year end

About Stoke Therapeutics

Stoke Therapeutics develops RNA-based medicines intended to address severe diseases by increasing protein expression. Using its TANGO approach, it designs antisense oligonucleotides to selectively restore protein levels. Its lead investigational medicine, zorevunersen, is in clinical development for Dravet syndrome. The company focuses on diseases involving protein insufficiency, particularly in the central nervous system and eye.

Generate the Stoke Therapeutics report

Stoke Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Stoke Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Stoke Therapeutics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.